Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3663575
Max Phase: Preclinical
Molecular Formula: C21H18F4N6O
Molecular Weight: 446.41
Molecule Type: Small molecule
Associated Items:
ID: ALA3663575
Max Phase: Preclinical
Molecular Formula: C21H18F4N6O
Molecular Weight: 446.41
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(c1cccc(F)c1-n1nccn1)N1C2CCC1C(Nc1ccc(C(F)(F)F)cn1)C2
Standard InChI: InChI=1S/C21H18F4N6O/c22-15-3-1-2-14(19(15)31-27-8-9-28-31)20(32)30-13-5-6-17(30)16(10-13)29-18-7-4-12(11-26-18)21(23,24)25/h1-4,7-9,11,13,16-17H,5-6,10H2,(H,26,29)
Standard InChI Key: LWXHAAFJSBPQID-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 446.41 | Molecular Weight (Monoisotopic): 446.1478 | AlogP: 3.68 | #Rotatable Bonds: 4 |
Polar Surface Area: 75.94 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 5.41 | CX LogP: 2.61 | CX LogD: 2.61 |
Aromatic Rings: 3 | Heavy Atoms: 32 | QED Weighted: 0.62 | Np Likeness Score: -1.34 |
1. (2015) Substituted 7-azabicyles and their use as orexin receptor modulators, |
2. (2016) Substituted 7-azabicycles and their use as orexin receptor modulators, |
Source(1):